CoChat

GLP1R expression and Parkinson’s disease and related disorders in GLP-1 receptor agonist-treated type 2 diabetes

The DOI matches its Crossref record; the references it cites are not checked yet.

Abstract

Preclinical and epidemiologic data suggest that glucagon-like peptide-1 receptor agonists (GLP-1RAs) may reduce the risk of Parkinson’s disease and related disorders (PDRD), yet clinical trial findings have been mixed, raising the possibility of biologically meaningful heterogeneity. We tested whether interindividual differences in systemic GLP1R expression are associated with PDRD risk among adults with type 2 diabetes initiating GLP-1RAs. We conducted an electronic health record-based new-user cohort study in the National Institutes of Health All of Us Research Program, focusing on adults with type 2 diabetes aged 50 years or older who initiated a GLP-1RA between 2005 and 2023 and had no prior PDRD or Alzheimer’s disease and related dementias (ADRD). Systemic GLP1R expression was genetically proxied by a 15-variant cis-expression quantitative trait locus (cis-eQTL) genetic risk score dichotomized at the cohort median. Follow-up ended at the earliest of incident PDRD, death or 1 October 2023. Hazard ratios (HR) were estimated using multivariable Cox proportional hazards models adjusting for baseline covariates, and incidence rates and rate differences per 1000 person-years were estimated using Poisson models. Prespecified sensitivity analyses excluded early outcome events and short drug exposure; an exploratory analysis evaluated incident ADRD. The cohort included 7039 initiators (3520 high versus 3519 low genetic score; mean age 61.7 ± 8.4 years; 59.8% female; mean follow-up 3.8 ± 3.1 years). Compared with the low-score group, the high-score group had a lower hazard of incident PDRD [HR 0.78; 95% confidence interval (CI) 0.62 to 0.98] and a lower incidence rate (rate difference −1.36 per 1000 person-years; 95% CI −2.51 to −0.20). Associations were consistent across sensitivity analyses. No association was observed for incident ADRD (HR 1.02; 95% CI 0.81 to 1.28). These findings link a mechanism-anchored genetic proxy for higher systemic GLP1R expression to a lower risk of incident PDRD among GLP-1RA-treated adults with type 2 diabetes. Systemic GLP1R-mediated pathways may be relevant to interindividual differences in observed PDRD risk, and genetic instruments for GLP1R expression may inform hypotheses for future PDRD trial design.

Overview

Integrity signals

Registry

Crossref · 10.1093/brain/awag130

Cites

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Citations

The citation lists are queued

They are fetched later and appear here then.

References 37 · Cited by 3

Metadata

Authors
Woo, K. A., Jang, Y., Kim, H.-J., & Park, P. J.
Affiliations
  • Harvard University (US)
  • Seoul National University (KR)
Corresponding author
  • Kim, Han-Joon
  • Park, Peter J
Venue
Brain
Published
2026-04-10
Volume
149
Issue
10
Pages
3431-3439
ISSN
  • 0006-8950 (ISSN-L)
  • 1460-2156
OpenAlex
W7154097040
Cited by
3
References
37
Citations by year
2026: 3
FWCI
12.60
Type
journal article
Language
en
Open access
closed
Locations
  • Brain (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • Korea Health Industry Development Institute
  • Ministry of Health & Welfare (RS-2024-00403047)
Topics
  • Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
Keywords
Parkinson's disease, GLP-1 receptor agonists, type 2 diabetes, Alzheimer's disease and related dementias, neurodegenerative disease risk, drug safety, All of Us, electronic health records, drug exposure duration
MeSH terms
Glucagon-Like Peptide-1 Receptor, Glucagon-Like Peptide-1 Receptor Agonists, Aged, Diabetes Mellitus, Type 2, Female, Humans, Hypoglycemic Agents, Male, Middle Aged, Parkinson Disease, Cohort Studies

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: GLP1R expression and Parkinson’s disease and related disorders in GLP-1 receptor agonist-treated type 2 diabetes. https://app.cochat.ai/papers/10.1093/brain/awag130
The paper
Woo, K. A., Jang, Y., Kim, H.-J., & Park, P. J. (2026). GLP1R expression and Parkinson’s disease and related disorders in GLP-1 receptor agonist-treated type 2 diabetes. Brain. https://doi.org/10.1093/brain/awag130

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.